Compound · clinical trials

Adebrelimab clinical trials

Also listed in trial records as SHR-1316, SHR-A1316, HTI-1088

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 151 trials in our China register that name Adebrelimab as an intervention. Synced 9 Nov 2026

151Current trials

107Recruiting now

72Lead sponsors

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Adebrelimab is named as an intervention in 151 current clinical trials in our China register. 107 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Suzhou Suncadia Biopharmaceuticals Co., Ltd (21). The most-studied condition is Pancreatic Cancer.

How Adebrelimab works

All drug targets →

Programmed cell death 1 ligand 1 inhibitor Inhibitor
Target: CD274 CD274 molecule
ChEMBL only

Other medicines acting on CD274

Durvalumab Atezolizumab Avelumab Envafolimab Sugemalimab KN046 Danburstotug Bintrafusp alfa

Diseases it has been tested for in clinical trials, by furthest phase

Biliary tract cancerPhase 3
Breast cancerPhase 3
Cervical cancerPhase 3
Colorectal cancerPhase 3
Gastric adenocarcinomaPhase 3
Gastric cancerPhase 3
Gastroesophageal junction adenocarcinomaPhase 3
Hepatocellular carcinomaPhase 3
Nasopharyngeal carcinomaPhase 3
Non-small cell lung carcinomaPhase 3

51 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297828, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13085, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Adebrelimab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting10771%
Not yet open3523%
Active, closed85%
By invitation11%

Trials by phase

Phase 210268%
Phase 1/22013%
Phase 3107%
Phase 185%
Not applicable43%
Phase 2/332%
Observational21%
Early Phase 121%

Clinical trials of Adebrelimab

151 trials

Study	Phase	Status	Lead sponsor	Registers
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) NCT06618664 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer NCT07111832 · ClinicalTrials.gov ↗ · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT07118527 · ClinicalTrials.gov ↗ · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer NCT07168200 · ClinicalTrials.gov ↗ · Advanced Cervical Cancer	Phase 3	Recruiting	Shanghai Shengdi Pharmaceutical Co., Ltd	China
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) NCT07229625 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer NCT07522151 · ClinicalTrials.gov ↗ · Locally Advanced Gastric or Gastroesophageal Junction Cancer	Phase 3	Recruiting	Shanghai Shengdi Pharmaceutical Co., Ltd	China
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer NCT07679360 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer NCT06791460 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent	Phase 2/3	Recruiting	Obstetrics & Gynecology Hospital of Fudan University	China
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer NCT07454720 · ClinicalTrials.gov ↗ · Locally Advanced Resectable Rectal Cancer	Phase 2/3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Reverse Triple Negative Immune Resistant Breast Cancer NCT05076682 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. NCT05753826 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Ovarian Diseases	Phase 2	Recruiting	Fujian Cancer Hospital	China
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma NCT06091124 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma of the Bladder, Bladder Cancer	Phase 2	Recruiting	RenJi Hospital	China
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer NCT06149130 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Tongji Hospital	China
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC NCT06165900 · ClinicalTrials.gov ↗ · Stereotactic Radiotherapy, Immunotherapy, Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors NCT06208462 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) NCT06261125 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Mian XI	China
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma NCT06266832 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma	Phase 2	Recruiting	Sir Run Run Shaw Hospital	China
The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma NCT06277791 · ClinicalTrials.gov ↗ · Clinical IVb Stage Oral Squamous Cell Carcinomas Patients	Phase 2	Recruiting	Hospital of Stomatology, Wuhan University	China
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06282445 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	China
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC NCT06296563 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Lei ZHAO	China
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma NCT06339619 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230 · ClinicalTrials.gov ↗ · HR Positive/HER2 Low Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Adebrelimab and Chemoradiotherapy in High-risk LANPC NCT06349889 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC NCT06360042 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma NCT06415669 · ClinicalTrials.gov ↗ · Gastric/Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis NCT06418594 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer Brain Metastases	Phase 2	Recruiting	Beijing 302 Hospital	China
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC NCT06424899 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	Zeng Jian	China
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer NCT06433609 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Recruiting	Beijing GoBroad Hospital	China
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection NCT06454578 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma NCT06455410 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC NCT06467617 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	Beijing Chest Hospital, Capital Medical University	China
Adebrelimab + Apatinib in SCLC Maintenance Therapy NCT06475209 · ClinicalTrials.gov ↗ · SCLC	Phase 2	Recruiting	Tang-Du Hospital	China
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study NCT06482788 · ClinicalTrials.gov ↗ · Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer NCT06483282 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 2	Recruiting	Jin Ying	China
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial NCT06485544 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC)	Phase 2	Recruiting	Tang-Du Hospital	China
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) NCT06506292 · ClinicalTrials.gov ↗ · Adebrelimab (SHR-1316), XELOX, GC/GEJC	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety NCT06531278 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic to Liver	Phase 2	Recruiting	Jiang Long	China
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) NCT06610734 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Recruiting	Sichuan University	China
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study NCT06663059 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Tang-Du Hospital	China
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma NCT06737913 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Sun Yat-sen University	China
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma NCT06749730 · ClinicalTrials.gov ↗ · Unresectable Biliary Tract Carcinoma	Phase 2	Recruiting	Henan Cancer Hospital	China
Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer NCT06765616 · ClinicalTrials.gov ↗ · Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy	Phase 2	Recruiting	Feng Tian	China
Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. NCT06771609 · ClinicalTrials.gov ↗ · Advanced Triple-negative Breast Cancer	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031 · ClinicalTrials.gov ↗ · HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer	Phase 2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis NCT06839560 · ClinicalTrials.gov ↗ · Brain Metastasis From Advanced HER2-negative Breast Cancer	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma NCT06869213 · ClinicalTrials.gov ↗ · Esophageal Cancer (EsC)	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour NCT06915142 · ClinicalTrials.gov ↗ · Advanced Malignant Tumour	Phase 2	Recruiting	Shandong Suncadia Medicine Co., Ltd	China
Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial NCT07007364 · ClinicalTrials.gov ↗ · Early-Stage Oral Squamous Cell Carcinoma	Phase 2	Recruiting	Jun Jia	China
Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07055841 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 2	Recruiting	Xiuping Ding	China
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer NCT07110571 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer NCT07131514 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Ruijin Hospital	China
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer NCT07135544 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Biliary Tract Cancer (CCA)	Phase 2	Recruiting	Yongjun Chen	China
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy NCT07141264 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage	Phase 2	Recruiting	Tang-Du Hospital	China
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer NCT07229729 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer NCT07241767 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent	Phase 2	Recruiting	Sun Yat-sen University	China
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors NCT07268040 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy NCT07309185 · ClinicalTrials.gov ↗ · Stomach Neoplasms	Phase 2	Recruiting	Shandong Tumor Hospital	China
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer NCT07353684 · ClinicalTrials.gov ↗ · Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach	Phase 2	Recruiting	Beijing Friendship Hospital	China
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study NCT07437898 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	The Affiliated Hospital of Putian University	China
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC NCT07452601 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Tang-Du Hospital	China
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer NCT07457346 · ClinicalTrials.gov ↗ · Head and Neck Cancer Squamous Cell Carcinoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer NCT07569679 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	Air Force Military Medical University, China	China
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer NCT07583550 · ClinicalTrials.gov ↗ · Lung, Radiotherapy	Phase 2	Recruiting	Jiangmen Central Hospital	China
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07638436 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Sun Yat-sen University	China
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies NCT07668453 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer NCT07704177 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer NCT07718490 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial NCT07731828 · ClinicalTrials.gov ↗ · Cervical Neoplasms	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC NCT07733830 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer NCT07770113 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC NCT07796113 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	First Affiliated Hospital Xi'an Jiaotong University	China
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC NCT07798947 · ClinicalTrials.gov ↗ · Limited-stage Small-cell Lung Cancer	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations NCT07824882 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Hansoh BioMedical R&D Company	China
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors NCT06417554 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma NCT06427239 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Recruiting	Fudan University	China
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer NCT06454448 · ClinicalTrials.gov ↗ · Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer	Phase 1/2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors NCT06474455 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer NCT06512051 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma NCT06639347 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors NCT06703177 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC NCT06754930 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer NCT06776770 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 1/2	Recruiting	Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center	China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer NCT07059221 · ClinicalTrials.gov ↗ · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma NCT07105592 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Fudan University	China
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors NCT07136142 · ClinicalTrials.gov ↗ · Malignant Solid Tumor	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors NCT07229586 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors NCT07296341 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Pancreatic Cancer With	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma	Phase 1/2	Recruiting	Tongji Hospital	China
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NCT07595172 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer	Phase 1/2	Recruiting	West China Hospital	China
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors NCT07806058 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies NCT06181032 · ClinicalTrials.gov ↗ · Biliary Tract Malignancies	Phase 1	Recruiting	First Affiliated Hospital of Fujian Medical University	China
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors NCT06332170 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors NCT06336707 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor NCT06350006 · ClinicalTrials.gov ↗ · CLDN18.2-positive Advanced Solid Tumor	Phase 1	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer NCT07886047 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC)	Phase 1	Recruiting	Second Xiangya Hospital of Central South University	China
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC NCT07434518 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC)	Observational	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study NCT07640048 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Observational	Recruiting	Peking Union Medical College Hospital	China
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer NCT06480864 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Not applicable	Recruiting	Yunpeng Liu	China
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer. NCT06613113 · ClinicalTrials.gov ↗ · MSS Metastatic Colorectal Cancer	Not applicable	Recruiting	Ningbo Medical Center Lihuili Hospital	China
Second-line Immunotherapy for ES-SCLC NCT06853678 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Not applicable	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma NCT06893887 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma(HCC)	Not applicable	Recruiting	Nanjing Tianyinshan Hospital	China
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma NCT07691762 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer NCT07896005 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer NCT07900789 · ClinicalTrials.gov ↗ · Systemic Treatment-naïve Pancreatic Cancer	Phase 3	Not yet open	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients NCT06335355 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2/3	Not yet open	Shanghai Shengdi Pharmaceutical Co., Ltd	China
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer NCT06177522 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Neoadjuvant Therapy	Phase 2	Not yet open	Jinling Hospital, China	China
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06236997 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma	Phase 2	Not yet open	Henan Cancer Hospital	China
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC NCT06648525 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Harbin Medical University	China
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer NCT06786312 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Not yet open	Fujian Cancer Hospital	China
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer NCT06916975 · ClinicalTrials.gov ↗ · Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic	Phase 2	Not yet open	Jin Xu	China
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer NCT07031154 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adebrelimab, Apatinib	Phase 2	Not yet open	The First Affiliated Hospital of Xiamen University	China
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer NCT07041437 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Not yet open	Fudan University	China
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen NCT07137039 · ClinicalTrials.gov ↗ · Locally Advanced Hypopharyngeal Cancer	Phase 2	Not yet open	The First Affiliated Hospital of Xiamen University	China
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy NCT07192848 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 2	Not yet open	Song Peng	China
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer NCT07317778 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD NCT07357532 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study NCT07398560 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Not yet open	The Third Affiliated Hospital of Harbin Medical University	China
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases NCT07466927 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer	Phase 2	Not yet open	Fudan University	China
Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC NCT07554768 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Chen Chunyan	China
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma NCT07682272 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk	Phase 2	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of Combination Therapy in Patients With Resectable Liver Cancer NCT07684040 · ClinicalTrials.gov ↗ · Liver Cancer (Primary and Metastatic)	Phase 2	Not yet open	Affiliated Hospital of Guangdong Medical University	China
The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer NCT07704645 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 2	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging NCT07770672 · ClinicalTrials.gov ↗ · Esophageal Cancer, ESCC	Phase 2	Not yet open	Tan Lijie	China
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer NCT07780721 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Not yet open	The Affiliated Hospital of Putian University	China
Perioperative Adebrelimab for Locally Advanced Cervical Cancer NCT07811375 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Not yet open	Anhui Provincial Hospital	China
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. NCT07863167 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer NCT07865611 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Cancer (MIBC)	Phase 2	Not yet open	Tongji Hospital	China
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC NCT07890636 · ClinicalTrials.gov ↗ · Lung Neoplasm Malignant	Phase 2	Not yet open	Ruijin Hospital	China
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer NCT07905950 · ClinicalTrials.gov ↗ · Locally Advanced Resectable Rectal Cancer	Phase 2	Not yet open	Henan Cancer Hospital	China
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ NCT07912957 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Not yet open	Fudan University	China
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer NCT07736612 · ClinicalTrials.gov ↗ · Pancreatic Cancer, RAS Mutations or Amplifications	Phase 1/2	Not yet open	Zhejiang University	China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors NCT06594874 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Advanced Solid Tumors	Phase 1	Not yet open	Jiangsu Hansoh Pharmaceutical Co., Ltd	China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors NCT06963502 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer	Phase 1	Not yet open	Jiangsu Hansoh Pharmaceutical Co., Ltd	China
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino NCT06156267 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Early Phase 1	Not yet open	Fudan University	China
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer NCT06735508 · ClinicalTrials.gov ↗ · NSCLC	Early Phase 1	Not yet open	Guangdong Provincial People's Hospital	China
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer NCT06773156 · ClinicalTrials.gov ↗ · Limited-stage Small Cell Lung Cancer (LS-SCLC)	Phase 2	By invitation	Second Affiliated Hospital of Nanchang University	China
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer NCT06247956 · ClinicalTrials.gov ↗ · Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer NCT06465563 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer NCT06599216 · ClinicalTrials.gov ↗ · Breast Cancer, HR+/HER2- Breast Cancer	Phase 2	Active, closed	Harbin Medical University	China
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis NCT06700421 · ClinicalTrials.gov ↗ · Unresectable Locally Advanced Non-small Cell Lung Cancer	Phase 2	Active, closed	Wei Zhou	China
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer NCT06766019 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	The First Affiliated Hospital with Nanjing Medical University	China
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer NCT07071714 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation NCT06385678 · ClinicalTrials.gov ↗ · Advanced KRAS G12D Mutant Solid Tumors	Phase 1/2	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer NCT07009457 · ClinicalTrials.gov ↗ · Widespread Small Cell Lung Cancer	Phase 1	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Adebrelimab

136 conditions

Pancreatic Cancer7 Advanced Solid Tumors6 Breast Cancer5 Non-Small Cell Lung Cancer4 Esophageal Cancer4 Esophageal Squamous Cell Carcinoma4 Small Cell Lung Cancer (SCLC)3 Non Small Cell Lung Cancer3 Biliary Tract Cancer3GC/GEJC3Gastric Cancer2 Nasopharyngeal Carcinoma2

All 136 conditions

Condition (as registered)	Trials
Pancreatic Cancer	7
Advanced Solid Tumors	6
Breast Cancer	5
Non-Small Cell Lung Cancer	4
Esophageal Cancer	4
Esophageal Squamous Cell Carcinoma	4
Small Cell Lung Cancer (SCLC)	3
Non Small Cell Lung Cancer	3
Biliary Tract Cancer	3
GC/GEJC	3
Gastric Cancer	2
Nasopharyngeal Carcinoma	2
Small Cell Lung Cancer	2
Advanced Breast Cancer	2
Biliary Tract Neoplasms Immunotherapy	2
Adebrelimab (SHR-1316)	2
Small Cell Lung Carcinoma	2
Head and Neck Squamous Cell Carcinoma	2
Hepatocellular Carcinoma	2
Advanced Urothelial Carcinoma	2
HR Positive/HER2 Low Breast Cancer	2
Small Cell Lung Cancer Extensive Stage	2
Radiotherapy	2
Colorectal Cancer	2
Non-small Cell Lung Cancer	2
Adebrelimab	2
Intrahepatic Cholangiocarcinoma	2
Immunotherapy	2
Intrahepatic Cholangiocarcinoma (Icc)	2
Locally Advanced Resectable Rectal Cancer	2
Brain Metastasis From Advanced HER2-negative Breast Cancer	1
Colorectal Cancer Metastatic	1
Locally Advanced Gastric or Gastroesophageal Junction Cancer	1
Gastroesophageal-junction Cancer	1
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	1
Liver Cancer (Primary and Metastatic)	1
Stomach Neoplasms	1
Unresectable Hepatocellular Carcinoma	1
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	1
Early-Stage Oral Squamous Cell Carcinoma	1
XELOX	1
Limited-stage Small Cell Lung Cancer (LS-SCLC)	1
HR+/HER2- Breast Cancer	1
Esophageal Squamous Cell Carcinoma (ESCC)	1
Squamous Cell Carcinoma of Head and Neck	1
Locally Advanced Head and Neck Squamous Cell Carcinoma	1
CLDN18.2-positive Advanced Solid Tumor	1
Advanced Biliary Tract Carcinoma	1
Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	1
Muscle-Invasive Bladder Cancer (MIBC)	1
Esophagogastric Junction Adenocarcinoma	1
Locally Advanced Cervical Cancer	1
Advanced KRAS G12D Mutant Solid Tumors	1
SCLC	1
Rectal Adenocarcinoma	1
Pancreatic Cancer Metastatic to Liver	1
Esophageal Cancer (EsC)	1
Carcinoma, Hepatocellular	1
Ovarian Cancer Recurrent	1
Metastatic Colorectal Cancer	1
Ovarian Neoplasms	1
Ovarian Diseases	1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)	1
Rectal Cancer	1
Advanced Stage Colorectal Cancer	1
Head and Neck Cancer Squamous Cell Carcinoma	1
Lung Neoplasm Malignant	1
Locally Advanced or Metastatic Pancreatic Cancer With	1
Resectable Non-small Cell Lung Cancer	1
Biliary Tract Cancer (CCA)	1
Nasopharyngeal Cancer	1
Unresectable Locally Advanced Non-small Cell Lung Cancer	1
Lung	1
Triple Negative Breast Cancer	1
Advanced Hepatocellular Carcinoma (HCC)	1
Advanced Hepatocellular Carcinoma	1
MSS Metastatic Colorectal Cancer	1
Advanced or Metastatic Non-small Cell Lung Cancer	1
Hepatocellular Carcinoma(HCC)	1
Decitabine	1
Metastatic Pancreatic Cancer	1
Biliary Tract Malignancies	1
Adenocarcinoma of GE Junction	1
Adenocarcinoma of Stomach	1
Neuroendocrine Carcinoma of the Bladder	1
Bladder Cancer	1
Hepatocellular Carcinoma Non-resectable	1
Clinical IVb Stage Oral Squamous Cell Carcinomas Patients	1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)	1
Apatinib	1
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk	1
Stereotactic Radiotherapy	1
Advanced Triple-negative Breast Cancer	1
Biliary Tract Neoplasms	1
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	1
Unresectable Biliary Tract Carcinoma	1
Cervical Neoplasms	1
Locally Advanced Hypopharyngeal Cancer	1
Biomarkers	1
HER2-negative Breast Cancer Brain Metastases	1
Gastric/Gastroesophageal Junction Adenocarcinoma	1
Advanced Solid Tumor	1
ESCC	1
RAS Mutations or Amplifications	1
Advanced Biliary Tract Cancer	1
Urothelial Carcinoma	1
Urothelial Carcinoma Recurrent	1
Small Cell Lung Cancer Limited Stage	1
Neoadjuvant Therapy	1
NSCLC	1
Pancreatic Ductal Adenocarcinoma (PDAC)	1
Locally Advanced and Metastatic Pancreatic Cancer	1
Non-squamous Non-small Cell Lung Cancer	1
SCLC,Extensive Stage	1
Ovarian Cancer	1
Gastric Adenocarcinoma	1
Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Pancreatic Cancer Non-resectable	1
Pancreatic Cancer Metastatic	1
Widespread Small Cell Lung Cancer	1
Limited-stage Small-cell Lung Cancer	1
Advanced Cervical Cancer	1
HER2-negative Breast Cancer	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Non-small Cell Lung Cancer (NSCLC)	1
Solid Tumor	1
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	1
Systemic Treatment-naïve Pancreatic Cancer	1
Lung Cancer	1
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer	1
Malignant Solid Tumors	1
Advanced Malignant Tumour	1
Malignant Solid Tumor	1
Triple-negative Breast Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	151	107

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Adebrelimab trials

How many clinical trials are testing Adebrelimab?

151 current trials in our China register name Adebrelimab (also registered as SHR-1316) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Adebrelimab trials recruiting patients?

Yes. 107 of the 151 trials are recruiting: 107 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Adebrelimab clinical trials?

Suzhou Suncadia Biopharmaceuticals Co., Ltd (21), Shanghai Hengrui Pharmaceutical Co., Ltd (11), Fudan University (8) and The First Affiliated Hospital with Nanjing Medical University (6), among 72 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Adebrelimab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Adebrelimab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Adebrelimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.